This systematic review demonstrates that modulation of the gut microbiota through dietary, probiotic, pharmacological, and personalized nutrition strategies consistently yields favorable effects on glycemic control, insulin sensitivity, and cardiometabolic outcomes in patients with type 2 diabetes mellitus (T2DM) or at high metabolic risk. This evidence concerns the gene INS and type 2 diabetes mellitus.